Moreover, they demonstrated that targeting cellular senescence with the BCL2 antagonist, ABT263 markedly reversed the hemodynamic and structural vascular changes of PAH, suggesting that cellular senescence was responsible for the development of irreversible arterial disease (10). The gene discussed is BCL2; the disease is pulmonary arterial hypertension.